SUMMARY OBJECTIVE: The objective of this study was to investigate factors influencing intrapartum fever in parturients receiving epidural labor analgesia. METHODS: This study included 410 parturients who received epidural labor analgesia at the authors’ hospital between February 2022 and February 2024. Participants were divided into a fever group (>37.5℃) and a control group (<37.5℃) based on their body temperature post-analgesia. General data, gestational comorbidities, and intrapartum-related conditions were compared. Influencing factors were analyzed using the chi-squared test and logistic regression. RESULTS: Intrapartum fever occurred in 90 parturients (22.0%). Univariate analysis indicated that maternal age (p=0.046), parity (p=0.042), oxytocin use (p=0.041), and timing of analgesia (p<0.001) were associated with intrapartum fever. Multivariate analysis revealed that the timing of analgesia (OR 3.612, 95%CI 1.533–8.510) and amniotic fluid contamination degrees I (OR 1.072, 95%CI 1.012–3.082) and II (OR 2.874, 95%CI 1.901–9.092) were independent risk factors. No significant differences were found between the fever and control groups in body mass index, gestational age, gestational comorbidities, and artificial membrane rupture (p>0.05). Intrapartum fever increased the rate of neonatal fever within 2 h after birth (41.7 vs 18.6%, p<0.05) but did not significantly affect other neonatal health indicators. CONCLUSION: Timing of analgesia and amniotic fluid contamination are significant factors influencing intrapartum fever in parturients receiving epidural labor analgesia. OBJECTIVE METHODS 41 authors 202 2024 >37.5℃ 375 37 5 (>37.5℃ <37.5℃ (<37.5℃ postanalgesia. postanalgesia post post-analgesia data comorbidities intrapartumrelated related compared chisquared chi squared regression RESULTS 9 22.0%. 220 22.0% . 22 0 (22.0%) p=0.046, p0046 p p=0.046 , 046 (p=0.046) p=0.042, p0042 p=0.042 042 (p=0.042) p=0.041, p0041 p=0.041 041 (p=0.041) p<0.001 p0001 001 (p<0.001 OR 3612 3 612 3.612 95CI CI 95 1.533–8.510 15338510 1 533 8 510 1072 072 1.072 1.012–3.082 10123082 012 082 2874 874 2.874 1.901–9.092 19019092 901 092 index p>0.05. p005 p>0.05 05 (p>0.05) 41.7 417 7 (41. 186 18 6 18.6% p<0.05 indicators CONCLUSION 4 20 >37.5 (>37.5 <37.5 (<37.5 22.0 (22.0% p004 p=0.04 04 (p=0.046 (p=0.042 (p=0.041 p<0.00 p000 00 (p<0.00 361 61 3.61 1.533–8.51 1533851 53 51 107 07 1.07 1.012–3.08 1012308 01 08 287 87 2.87 1.901–9.09 1901909 09 p00 p>0.0 (p>0.05 41. (41 18.6 p<0.0 >37. (>37. <37. (<37. 22. (22.0 p=0.0 (p=0.04 (p<0.0 36 3.6 1.533–8.5 153385 10 1.0 1.012–3.0 101230 28 2.8 1.901–9.0 190190 p0 p>0. (p>0.0 (4 18. p<0. >37 (>37 <37 (<37 (22. p=0. (p=0.0 (p<0. 3. 1.533–8. 15338 1. 1.012–3. 10123 2. 1.901–9. 19019 p>0 (p>0. ( p<0 >3 (>3 <3 (<3 (22 p=0 (p=0. (p<0 1.533–8 1533 1.012–3 1012 1.901–9 1901 p> (p>0 p< > (> < (< (2 p= (p=0 (p< 1.533– 153 1.012– 101 1.901– 190 (p> (p= (p 1.533 15 1.012 1.901 19 1.53 1.01 1.90 1.5 1.9

ABSTRACT Purpose: The active melanocytes in the skin were affected by hormones and ultraviolet (UV) irradiation. Licorice zinc has a whitening effect, which may have a prominent potential in the treatment of pigmented skin disease. Methods: Modeling chloasma Balb/c mice by daily progesterone injection (15 mg/kg) and ultraviolet B (UVB) irradiation (λ = 312 nm, 2 h/day) for 30 days. Then, mice were given 0.65, 1.3, and 2.6 (g/kg) of licorice zinc and tranexamic acid 250 mg daily by oral administration for 14 days, respectively. Hematoxylin and eosin and Fontana-Masson staining, and Western blotting (WB) were performed to test the inhibitory of melanogenesis and activation of c-Jun-N-terminal (JNK)/p38 mitogen-activated protein kinases (MAPK) for licorice zinc. Melanogenesis was induced by α-melanocyte-stimulating hormone in vitro. Cell counting kit-8, melanin content determination, and WB were performed to verify the inhibitory effect of licorice zinc on melanogenesis. Results: The present study showed that licorice zinc decreased melanin formation, cutaneous tissue injury, and the phosphorylation of JNK and P38MAPK, which was caused by UVB irradiation in vivo. In vitro, licorice zinc showed opposite effects from JNK/p38 activator. Meanwhile, tyrosinase-related protein-1, tyrosinase, and microphthalmia-associated transcription factor were decreased too. Conclusions: Licorice zinc induced a decrease in melanin synthesis by inhibiting the JNK and the P38MAPK signaling pathway, suggesting licorice zinc is a potential agent of anti-chloasma. Purpose UV (UV disease Methods Balbc Balb c 15 (1 mg/kg mgkg kg (UVB λ 31 nm h/day hday h day 3 days Then 065 0 65 0.65 13 1 1.3 26 6 2. g/kg gkg g (g/kg 25 respectively FontanaMasson Fontana Masson staining (WB cJunNterminal Jun N terminal JNKp38 JNKp /p38 p38 p (JNK)/p3 mitogenactivated mitogen activated MAPK (MAPK αmelanocytestimulating α melanocyte stimulating vitro kit8, kit8 kit 8, 8 kit-8 determination Results formation injury PMAPK P vivo JNK/p3 activator Meanwhile tyrosinaserelated tyrosinase related protein1, protein1 1, protein-1 microphthalmiaassociated microphthalmia associated too Conclusions pathway antichloasma. antichloasma anti chloasma. anti-chloasma ( 06 0.6 1. JNKp3 /p3 p3 (JNK)/p kit- JNK/p protein- 0. /p

Resumo Introdução A rinite alérgica é uma forma de inflamação da mucosa nasal mediada por IgE em resposta a alérgenos específicos, resulta em sintomas típicos. Objetivos Comparar a eficácia clínica da neurectomia nasal posterior com ou sem neurectomia faríngea para o tratamento da rinite alérgica perene de moderada a grave. Além disso, comparar a gravidade das comorbidades, inclusive tosse crônica e asma, entre os pacientes nesses dois grupos de tratamento cirúrgico. Método Foram incluidos neste ensaio clínico randomizado e designados para o grupo controle (neurectomia nasal posterior) ou para o grupo experimental (neurectomia nasal posterior + neurectomia faríngea) 52 pacientes. A escala visual analógica e o questionário de qualidade de vida na rinoconjuntivite (rhinoconjunctivitis quality of life questionnaire) foram usados para comparar as diferenças nos sintomas dos pacientes entre o período inicial e 6, 12 e 24 meses após o tratamento. Além disso, a tosse e os sintomas de asma dos pacientes foram monitorados durante o acompanhamento por meio da escala visual analógica e do teste de controle da asma (asthma control test ), respectivamente. Resultados Nenhuma diferença significante nos escores pré‐operatórios foi evidenciada entre os grupos (p > 0,05). Aos seis meses pós‐tratamento, houve diferenças significantes nos escores da escala visual analógica, no questionário de qualidade de vida na rinoconjuntivite e no teste de controle de asma em relação aos valores basais dos pacientes no grupo experimental e no grupo controle (p < 0,05), o que permaneceu verdadeiro após 12 e 24 meses de acompanhamento. Não foram observadas diferenças significantes nos escores da escala visual analógica e nem no questionário de qualidade de vida para conjuntivite ou no teste de controle da asma entre os dois grupos de tratamento em qualquer momento do acompanhamento pós‐operatório (p > 0,05), enquanto a gravidade da tosse foi significantemente reduzida no grupo experimental em relação ao grupo controle (p < 0,05). Conclusão A neurectomia nasal posterior pôde ser feita com segurança com ou sem neurectomia faríngea para o tratamento eficaz da rinite alérgica. O tratamento combinado com neurectomia nasal posterior e neurectomia faríngea pode oferecer mais benefício do que a neurectomia nasal posterior isolada para o tratamento de pacientes com rinite alérgica e tosse crônica. específicos típicos grave disso comorbidades cirúrgico 5 rhinoconjunctivitis questionnaire 6 1 2 asthma , ) respectivamente préoperatórios pré operatórios p 0,05. 005 0,05 . 0 05 0,05) póstratamento pós pós‐tratamento 0,05, pósoperatório operatório 00 0,0 0,

Abstract Introduction Allergic rhinitis is a form of IgE mediated inflammation of the nasal mucosa in response to specific allergens, resulting in typical symptoms. Objectives This study was designed with the primary goal of comparing the clinical efficacy of posterior nasal neurectomy with or without pharyngeal neurectomy for the treatment of moderate-to-severe perennial allergic rhinitis. Secondary study aims included a comparison of the severity of comorbidities, including chronic cough and asthma, between patients in these two surgical treatment groups. Methods A total of 52 patients were enrolled in this randomized controlled trial and were assigned to either the control group (posterior nasal neurectomy) or the experimental group (posterior nasal neurectomy + pharyngeal neurectomy). The visual analog scale and rhinoconjunctivitis quality of life questionnaire were used to compare the differences in patient symptoms between baseline and 6-, 12-, and 24-months post-treatment. In addition, patient cough and asthma symptoms were monitored during follow-up via visual analog scale and asthma control test respectively. Results No significant differences in preoperative scores were evident between groups (p> 0.05). At 6-months post-treatment, there were significant differences in visual analog scale, rhinoconjunctivitis quality of life questionnaire, and asthma control test scores relative to baseline values in experimental group and control group patients (p< 0.05), and this remained true upon 12- and 24-month follow-up. No significant differences in visual analog scale, rhinoconjunctivitis quality of life questionnaire, or asthma control test scores were observed between the two treatment groups at any postoperative follow-up time point (p> 0.05), while coughing severity was found to be significantly reduced in the experimental group relative to the control group (p< 0.05). Conclusion posterior nasal neurectomy can be safely implemented with or without pharyngeal neurectomy in order to effectively treat allergic rhinitis. Combined posterior nasal neurectomy and pharyngeal neurectomy treatment may offer greater value than posterior nasal neurectomy alone for the treatment of allergic rhinitis patients with chronic cough. allergens moderatetosevere moderate severe comorbidities 5 neurectomy. . 6, 6 , 6- 12, 12 24months months 24 posttreatment. posttreatment post treatment. post-treatment addition followup follow up respectively p> p (p 0.05. 005 0.05 0 05 0.05) 6months posttreatment, treatment, p< 0.05, 24month month followup. up. 1 2 00 0.0 0.

Bi2MoO6 nanosheets were synthesized by a hydrothermal method. Morphology and structure of the Bi2MoO6 nanosheets were analyzed by SEM, XRD, N2 adsorption techniques and XPS. Gas-sensing properties of the as-prepared Bi2MoO6 sensors were also systematically investigated. The results showed the reaction temperature greatly affected the morphology and structure of as-prepared Bi2MoO6 nanosheets. When the reaction temperature reached 170 ºC, the morphology of the Bi2MoO6 nanosheets tended to regular, and pure Bi2MoO6 nanosheets were obtained. The operating temperature determined the gas-sensing properties of the Bi2MoO6 sensor. At this optimal operating temperature of 300 ºC, the sensitivity of the Bi2MoO6 sensor towards 20 ppm nitrogen oxide (NO) reached a maximum of 3.13. With the increase of the nitrogen oxide (NO) concentration, the sensitivity of the Bi2MoO6 sensor also rapidly increased, and displayed an almost linear relationship between them. Additionally, the Bi2MoO6 sensor demonstrated excellent selectivity with respect to several typical interfering gases.

We report a case of drug-induced lupus (DIL) on a Chinese woman caused by methimazole (MMI). This report discusses DIL associated with MMI and briefly reviewed the literature concerning to anti-thyroid DIL.

Hashimoto’s thyroiditis (HT) is considered to be mediated mainly by Th1 cells, but it is not known whether Graves’ disease (GD) is associated with Th1 or Th2 predominance. Th17 cells, a novel subset of Th cells, play a crucial role in the pathogenesis of various autoimmune disorders. In the present study, the expression of IL-17A and IFN-γ was investigated in patients with HT or GD. mRNA expression of IL-17A and IFN-γ in peripheral blood mononuclear cells (PBMC) from 43 patients with autoimmune thyroid disease (AITD) and in thyroid tissues from 40 AITD patients were measured by real-time qRT-PCR. The protein expression of IL-17A and IL-23p19 was examined by immunohistochemistry in thyroid tissues from 28 AITD patients. The mRNA levels of IL-17A and IFN-γ were higher in both PBMC and thyroid tissues of HT patients than in controls (mRNA levels are reported as the cytokine/β-actin ratio: IL-17 = 13.58- and 2.88-fold change and IFN-γ = 16.54- and 2.74-fold change, respectively, P < 0.05). Also, the mRNA levels of IL-17A and IFN-γ did not differ significantly in GD patients (P > 0.05). The high protein expression of IL-17A (IOD = 15.17 ± 4.8) and IL-23p19 (IOD = 16.84 ± 7.87) in HT was confirmed by immunohistochemistry (P < 0.05). The similar high levels of IL-17A and IFN-γ suggest a mixed response of Th17 and Th1 in HT, where both cells may play important roles in the destruction procedure by cell-mediated cytotoxicity.